The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis
Open accessAbstract
Background: We aimed to elucidate the relationship between serum myostatin levels and other markers including skeletal muscle mass and to investigate the influence of serum myostatin levels on survival for patients with liver cirrhosis (LC). Methods: A total of 198 LC subjects were analysed in this study. Myostatin levels were measured using stored sera. We retrospectively investigated the relationship between myostatin level and other markers, and the influence of myostatin level on overall survival (OS). Assessment of skeletal muscle mass was performed using the psoas muscle index (PMI) on computed tomography images at baseline. PMI indicates the sum of bilateral psoas muscle mass calculated by hand tracing at the lumber three level on computed tomography images divided by height squared (cm 2/m 2). The study cohort was divided into two groups based on the median myostatin value in each gender. Results: Our study cohort included 108 male and 90 female patients with a median age of 67.5 years. The median (range) myostatin level for male patients was 3419.6 pg/mL (578.4–12897.7 pg/mL), whereas that for female patients was 2662.4 pg/mL (710.4–8782.0 pg/mL) (P = 0.0024). Median (range) serum myostatin level for Child–Pugh A patients (n = 123) was 2726.0 pg/mL (578.4–12667.2 pg/mL), whereas that for Child–Pugh B or C patients (n = 75) was 3615.2 pg/mL (663.3–12897.7 pg/mL) (P = 0.0011). For the entire cohort, the 1‐, 3‐, 5‐, and 7‐year cumulative OS rates were 93.94%, 72.71%, 50.37%, and 38.47%, respectively, in the high‐myostatin group and 96.97%, 83.27%, 73.60%, and 69.95%, respectively, in the low‐myostatin group (P = 0.0001). After excluding hepatocellular carcinoma patients (at baseline) from our analysis (n = 158), the 1‐, 3‐, 5‐, and 7‐year cumulative OS rates were 96.0%, 77.93%, 52.97%, and 39.08%, respectively, in the high‐myostatin group and 96.39%, 87.58%, 77.63%, and 73.24%, respectively, in the low‐myostatin group (P = 0.0005). Higher age (P = 0.0111) and lower PMI (P < 0.0001) were identified as significant predictors of poorer OS in our multivariate analysis, while higher serum myostatin (P = 0.0855) tended to be a significant adverse predictor. In both genders, PMI, serum albumin, prothrombin time, and branched‐chain amino acid to tyrosine ratio showed a significantly inverse correlation with myostatin levels, and serum ammonia levels showed a significantly positive correlation with myostatin levels. Conclusions: Higher serum myostatin levels correlated with muscle mass loss, hyperammonemia, and impaired protein synthesis, as reflected by lower serum albumin levels and lower branched‐chain amino acid to tyrosine ratio levels. High serum myostatin levels were also associated with a reduced OS rate in LC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Cruz-Jentoft, A. J., Landi, F., Schneider, S. M., Zuniga, C., Arai, H., Boirie, Y., Chen, L.-K., Fielding, R. A., Martin, F. C., Michel, J.-P., et al. (2014) · Age and Ageing · doi:10.1093/ageing/afu115 · Cited by 1,963
Sarcopenia from mechanism to diagnosis and treatment in liver disease
Dasarathy, S., & Merli, M. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.040 · Cited by 608
Gonzalez-Cadavid, N. F., Taylor, W. E., Yarasheski, K., Sinha-Hikim, I., Ma, K., Ezzat, S., Shen, R., Lalani, R., Asa, S., Mamita, M., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14938 · Cited by 571 · cited 1×
“Recent molecular investigations, using muscle biopsy specimens for patients with LC and healthy controls, have demonstrated increased skeletal muscle expression and almost four-fold higher plasma concentrations of myostatin in LC patients as compared with controls.(23,30,43) However, in our data, serum myostatin level…”
ResultPivotal role of glutamine synthetase in ammonia detoxification
Hakvoort, T. B. M., He, Y., Kulik, W., Vermeulen, J. L. M., Duijst, S., Ruijter, J. M., Runge, J. H., Deutz, N. E. P., Koehler, S. E., & Lamers, W. H. (2017) · Hepatology · doi:10.1002/hep.28852 · Cited by 173
Cited by
EASL Clinical Practice Guidelines on nutrition in chronic liver disease
Merli, M., Berzigotti, A., Zelber-Sagi, S., Dasarathy, S., Montagnese, S., Genton, L., Plauth, M., & Parés, A. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.06.024 · Cited by 1,130
Sarcopenia in cirrhosis: from pathogenesis to interventions
Ebadi, M., Bhanji, R. A., Mazurak, V. C., & Montano-Loza, A. J. (2019) · Journal of Gastroenterology · doi:10.1007/s00535-019-01605-6 · Cited by 292
Skeletal muscle wasting in chronic heart failure
Suzuki, T., Palus, S., & Springer, J. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12387 · Cited by 134
Oh, S., Tsujimoto, T., Kim, B., Uchida, F., Suzuki, H., Iizumi, S., Isobe, T., Sakae, T., Tanaka, K., & Shoda, J. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100253 · Cited by 77
Sarcopenic Obesity in Liver Cirrhosis: Possible Mechanism and Clinical Impact
Nishikawa, H., Enomoto, H., Nishiguchi, S., & Iijima, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041917 · Cited by 56
Self-citationAlexopoulos, T., Vasilieva, L., Kontogianni, M. D., Tenta, R., Georgiou, A., Stroumpouli, E., Mani, I., & Alexopoulou, A. (2021) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00184.2021 · Cited by 40
Candidate rejuvenating factor GDF11 and tissue fibrosis: friend or foe?
Frohlich, J., & Vinciguerra, M. (2020) · GeroScience · doi:10.1007/s11357-020-00279-w · Cited by 28
Sharma, B. C., Maharshi, S., Sachdeva, S., Mahajan, B., Sharma, A., Bara, S., Srivastava, S., Kumar, A., Dalal, A., & Sonika, U. (2023) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16266 · Cited by 11
“37 Our study showed improvement in myo-statin with nutritional therapy and worsening in the no nutritional therapy group.”
Method
Metadata
- Authors
- Nishikawa, H., Enomoto, H., Ishii, A., Iwata, Y., Miyamoto, Y., Ishii, N., Yuri, Y., Hasegawa, K., Nakano, C., Nishimura, T., Yoh, K., Aizawa, N., Sakai, Y., Ikeda, N., Takashima, T., Takata, R., Iijima, H., & Nishiguchi, S.
- Venue
- Journal of Cachexia, Sarcopenia and Muscle
- Publisher
- Wiley
- Published
- 2017-06-18
- Volume
- 8
- Issue
- 6
- Pages
- 915-925
- ISSN
- 2190-5991 (ISSN-L)
- 2190-6009
- OpenAlex
- W2627050072
- Cited by
- 196
- References
- 6
- FWCI
- 11.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.